2016 Volume 26 Issue 1 Pages 49-55
Twenty-one patients who had laryngeal squamous cell carcinoma were treated with radiotherapy and concomitant intra-arterial cisplatin (RADPLAT) between 2004 and 2010 at the Kurume University Hospital. Eleven of the 21 patients had supraglottic cancer, 7 had glottic cancer, and 3 had subglottic cancer. Six patients were at Stage II, 11 were at Stage III, and 4 were at Stage IV A. All of the patients could be treated with RADPLAT without having to stop the treatment. As a result, the 5-year laryngeal preservation rate of supraglottic cancer, glottis cancer and subglottic cancer were 82%, 100% and 100%, respectively. The 5-year overall survival rate of supraglottic cancer, glottic cancer and subglottic cancer were 91%, 100% and 100%, respectively. Side effects of Grade 4 were not observed. RADPLAT for laryngeal cancer may be a more effective treatment which allows laryngeal preservation.
